GMAB

Business Context and Reporting Period

Company: Genmab A/S (Genmab)
Filing Type: Annual Report on Form 20-F
Reporting Period: Fiscal year ended December 31, 2022
Reporting Currency: Danish Kroner (DKK)
Accounting Standard: International Financial Reporting Standards (IFRS)

Genmab is an international biotechnology company focused on developing innovative antibody therapeutics. The company operates primarily through strategic collaborations with major pharmaceutical partners (Janssen, Novartis, AbbVie, Seagen, Horizon) for the development and commercialization of its products. Genmab is transitioning into a commercial-stage company, having launched its first proprietary product, Tivdak (tisotumab vedotin), in the U.S. and Japan.

Key Financial Metrics

Note: Specific consolidated financial statement totals (e.g., total revenue, net income, cash flow) are incorporated by reference to the Annual Report 2022 and are not explicitly detailed in the provided text. The following metrics are derived from the text provided.

• Revenue Composition (2022):
  • Total revenue from Janssen collaborations: DKK 10,620 million (73% of total revenue).
  • DARZALEX (daratumumab) specific revenue from Janssen: DKK 10,056 million (95% of Janssen revenue).
  • Revenue breakdown from Janssen: 80% royalties, 12% milestone revenue, 6% reimbursement revenue, 2% collaboration revenue.
• Outstanding Shares (as of period end):
  • Ordinary Shares: 65,961,573
  • American Depositary Shares (ADS): 46,612,010
• Employee Count: 1,660 employees as of December 31, 2022 (up from 548 in 2019).
• Compensation (2022):
  • Board Remuneration: DKK 12.6 million.
  • Executive Management Remuneration: DKK 114.4 million.
  • Senior Management Remuneration: DKK 138.2 million.

Material Changes and Operational Highlights

• Revenue Concentration: While Janssen remains the primary revenue driver, the percentage of total revenue derived from Janssen decreased from 81% in 2021 to 73% in 2022, driven by milestone achievements with AbbVie.
• Commercialization Launch: Genmab became a commercial-stage company with the FDA accelerated approval of Tivdak (tisotumab vedotin) in September 2021. In 2022, the company began co-promoting Tivdak in the U.S. with Seagen and leading commercial operations in Japan.
• Regulatory Submissions:
  • Submitted a Biologics License Application (BLA) for epcoritamab to the FDA in September 2022 (accepted with Priority Review, target action date May 21, 2023).
  • Submitted a Japan New Drug Application (JNDA) for epcoritamab in December 2022.
• Collaboration Changes:
  • AbbVie: In June 2022, AbbVie discontinued co-development of DuoHexaBody-CD37. Genmab became solely responsible for its development as of December 24, 2022.
  • Janssen: A second arbitration was commenced in June 2022 regarding DARZALEX FASPRO milestone payments and royalty terms.

Guidance, Outlook, Risks, and Contingencies

Outlook and Guidance

Genmab expects to incur increased research and development (R&D) and selling, general, and administrative (SG&A) expenses in future periods as it advances its proprietary pipeline and expands commercialization capabilities. The company anticipates that DARZALEX will continue to account for a substantial portion of revenue in the near term. Management expects to report results or preliminary data for several clinical trials in 2023.

Material Risks and Contingencies

• Arbitration with Janssen:
  • First Arbitration (Final): In April 2022, a tribunal ruled that Janssen's royalty obligation extends through the expiration of Genmab-owned patents (late 2020s/early 2030s) but not Janssen-owned patents. The tribunal also ruled Janssen may offset royalties against payments made to Halozyme for SC formulation technology.
  • Second Arbitration (Ongoing): Commenced June 9, 2022. Genmab is seeking $405 million plus interest in accrued milestone payments for DARZALEX FASPRO and a declaration of a new 13-year royalty term.
• Dependency on Partners: Financial results are substantially dependent on the commercial success of DARZALEX (Janssen) and the ability of partners to expand indications for other products (RYBREVANT, TECVAYLI, Kesimpta, TEPEZZA).
• Regulatory and Clinical Risks: High risk of failure in clinical trials; potential delays in regulatory approvals for epcoritamab and other candidates; reliance on third-party CMOs for manufacturing.
• Intellectual Property: Risks related to patent expiration (daratumumab patents expire late 2020s/early 2030s), biosimilar competition, and potential infringement claims.
• Foreign Exchange: Significant exposure to USD/DKK exchange rates as royalties and milestones are often denominated in USD but reported in DKK.

Key Facts for Investor Verification

• Revenue Dependency: Verify the extent of revenue concentration in Janssen (73% of total revenue in 2022) and the specific impact of the ongoing arbitration on future royalty streams.
• Arbitration Outcome: Monitor the status and potential resolution of the second arbitration with Janssen regarding the $405 million milestone claim and royalty term for DARZALEX FASPRO.
• Epcoritamab Approval: Track the FDA decision on the epcoritamab BLA (target action date May 21, 2023) and subsequent commercialization plans with AbbVie.
• Commercialization Costs: Assess the burn rate associated with building in-house commercial infrastructure for Tivdak and future proprietary products versus royalty income.
• Patent Expiry Timeline: Confirm the specific expiration dates of key patents for daratumumab (late 2020s/early 2030s) and the potential impact of biosimilar entry.
• AbbVie Collaboration Scope: Verify the financial implications of Genmab taking sole responsibility for DuoHexaBody-CD37 development following AbbVie's exit.